Compound ID | 2892

Update compound information

SPR720 (phosphate prodrug of SPR719)

Synonym(s): Fobrepodacin

Class: Small molecule antibacterial agent

Details of activity: Active against Mycobacterium avium, Mycobacterium kansasii, Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera; DNA gyrase inhibitor (targeting GyrB subunit)/ bacterial topoisomerase inhibitor
Description: Synthetic compound; for nontuberculous mycobacterial pulmonary infection; rapidly converted to the active moiety SPR719 in vivo
Institute where first reported: Spero Therapeutics, Inc., Cambridge, Massachusetts, USA
Year first mentioned: 2018
Highest developmental phase: Phase 2 (NCT05496374)
Development status: Active (as of 2024)
Chemical structure(s):
Click here for structure editor
Molecular weight: 508.44
Iso. SMILES: CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)OP(=O)(O)O
InChI Key: COTQDURISRILOR-CQSZACIVSA-N
Can. SMILES: CCNC(=O)NC1=NC2=C([C@H]3CCCO3)C(=C(C=C2N1)C4=CN=C(C(C)(C)OP(=O)(O)O)N=C4)F
InChI: InChI=1S/C21H26FN6O6P/c1-4-23-20(29)28-19-26-13-8-12(16(22)15(17(13)27-19)14-6-5-7-33-14)11-9-24-18(25-10-11)21(2,3)34-35(30,31)32/h8-10,14H,4-7H2,1-3H3,(H2,30,31,32)(H3,23,26,27,28,29)/t14-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/68108988
Guide to Pharmacology: fobrepodacin
Citation: https://journals.asm.org/doi/10.1128/aac.01208-21

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.